By: Benzinga
UPDATE: Jefferies Reiterates Valeant Pharmaceuticals at Buy Following Cash Tender Offer
Jefferies maintained Valeant Pharmaceuticals (NYSE: VRX ) with a Buy rating and a $77.00 price target. Jefferies analyst Corey Davis commented, "This morning, VRX announced a ~$360M all-cash tender offer for Obagi Medical Products. It's not a “transformative” deal, but mildly accretive and a solid strategic fit with its new
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here